Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous tumor-infiltrating lymphocytes GT307

A preparation of autologous tumor-infiltrating lymphocytes (TILs) derived from each patient's resected tumor and edited with the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) system to eliminate the expression of as of yet not elucidated immunoregulatory targets, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, autologous TILs GT307 specifically recognize and kill the patient's tumor cells. The knockout of the immunoregulatory targets may enhance the proliferation and cytokine release of the TILs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CRISPR-edited TILs GT307
autologous TILs GT307
Code name:GT 307
GT-307
GT307
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search